Growth Metrics

Travere Therapeutics (TVTX) Income towards Parent Company: 2011-2024

Historic Income towards Parent Company for Travere Therapeutics (TVTX) over the last 14 years, with Dec 2024 value amounting to -$915,000.

  • Travere Therapeutics' Income towards Parent Company rose 25806.00% to $25.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$28.3 million, marking a year-over-year decrease of 1014.35%. This contributed to the annual value of -$915,000 for FY2024, which is 100.35% down from last year.
  • According to the latest figures from FY2024, Travere Therapeutics' Income towards Parent Company is -$915,000, which was down 100.35% from $264.9 million recorded in FY2023.
  • In the past 5 years, Travere Therapeutics' Income towards Parent Company ranged from a high of $264.9 million in FY2023 and a low of -$169.4 million during FY2020.
  • Over the past 3 years, Travere Therapeutics' median Income towards Parent Company value was $53.0 million (recorded in 2022), while the average stood at $105.7 million.
  • Per our database at Business Quant, Travere Therapeutics' Income towards Parent Company soared by 400.01% in 2023 and then plummeted by 100.35% in 2024.
  • Travere Therapeutics' Income towards Parent Company (Yearly) stood at -$169.4 million in 2020, then surged by 121.96% to $37.2 million in 2021, then surged by 42.43% to $53.0 million in 2022, then soared by 400.01% to $264.9 million in 2023, then slumped by 100.35% to -$915,000 in 2024.